According to a Moderna spokeswoman, the pharmaceutical behemoth plans to provide vaccinations for heart disease, cancer, and other serious illnesses by 2030.
During a chat with The Guardian this past weekend, Paul Burton, the company’s chief medical officer, praised the “tremendous promise” of vaccination research.
Some researchers claimed that 15 years of advancement were compressed into 12 to 18 months as a result of the company’s game-changing vaccine against COVID-19.
Burton shared that: “I think we will have mRNA based therapies for rare diseases that were undruggable previously, and I think that ten years from now, we’ll be approaching a world where you can truly identify a genetic cause of a disease and, with general simplicity, go and edit it out and repair it using mRNA based technology.”
The COVID-19 vaccines function by injecting the genetic information for the spike protein that covers its surface.
The body’s cells are given instructions to create harmless spike copies via the code known as the mRNA, which is contained in a tiny ball of fat.
These copies help the immune system develop an ability to identify the actual virus upon encountering it in the wild.
That being said, it appears that Moderna is employing the same technique to produce vaccinations that focus on particular kinds of cancers.
FDA designated the company’s cancer vaccine as a breakthrough medicine in February, accelerating the regulatory review process in light of positive results in treating melanoma patients.
The status of an anti-respiratory syncytial virus (RSV) vaccination was also announced back in January.
It was shown to be 83.7% effective in avoiding at least two symptoms, such as fever and coughing, in persons 60 and older.
Burton told the publication that “We’ll have that vaccine and it’ll be highly effective, and it’ll save hundreds of thousands, if not millions of lives. I think that we will be able to offer personalized cancer vaccines against many different tumor types to people all around the world. I believe that what we’ve learned in recent months is that if you ever thought mRNA was just for infectious diseases, or solely for COVID, the evidence is that that’s absolutely not the case now. It can get applied to all sorts of disease areas; we’re in cancer, infectious diseases, cardiovascular diseases, autoimmune diseases, rare diseases.”
Additionally, according to Burton, a single injection might treat a variety of respiratory illnesses like COVID, the flu, and RSV to name just a few.
According to Moderna, they began creating its mRNA technology platform back in 2010, which aided the business in producing its COVID-19 vaccine promptly once the pandemic began in early 2020.
And by the end of the same year, US regulators had approved the use of injections made by Pfizer and Moderna after clinical studies showed that both were very successful, making the two companies well-known.